GeneriCo News Industry News Press Releases

Pharmaceuticals Veteran George R. Stevenson Joins the GeneriCo Board of Directors

  St. Louis, MO, January 26, 2017 – GeneriCo, LLC (“GeneriCo”), a global generic specialty pharmaceutical company, is pleased to announce that George R. Stevenson has joined the Company’s Board of Directors as the new Chairman of the Board. Mr. Stevenson brings deep generic and brand pharmaceutical expertise to the GeneriCo Board and is a … Continued

Industry News

CMS Understanding Recent Trends in Generic Drug Prices

Generic drugs have for several decades offered relief from rising prescription drug costs. This occurs because there is robust competition among multiple interchangeable products that drive prices for generic drugs to be a fraction of that of the corresponding brand name drug.

Industry News

Early IPRs Challenging Biologic Patents: What We Know

USA June 17, 2016 Multiple IPRs challenging patents covering brand-name biologics have now been filed by biosimilar developers, for reasons we recently discussed, as well as by other entities. Institution decisions in these early IPRs and a small number of final written decisions suggest that broad mechanistic claims as well as follow-on patent claims—such as those covering … Continued

Industry News

First Enbrel Biosimilar Recommended for Approval in Europe

The EMA has recommended Benepali, an etanercept biosimilar for the treatment of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis. By: Megan Brooks   The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has recommended approval of Benepali, a biosimilar of etanercept (Enbrel, Immunex and Amgen), for treatment of rheumatoid arthritis … Continued

Industry News

Top 20 generics companies by 2014 revenue

To most of the world, the term “generic” suggests something everyday, common or bland, but to the drug industry generic is anything but bland. It represents a high-volume, low-margin business that is certainly not for sissies. It calls for scientific and manufacturing skills, a superb sales operation, and fortitude. It comes with risks but also … Continued